home / stock / xrtx:cc / xrtx:cc news

XRTX:CC News and Press, Xortx Therapeutics Inc. From 11/03/22

Stock Information
Company Name: Xortx Therapeutics Inc.
Stock Symbol: XRTX:CC
Market: TSXVC
Website: xortx.com
Menu
XRTX:CC XRTX:CC Quote XRTX:CC Short XRTX:CC News XRTX:CC Articles XRTX:CC Message Board
Get XRTX:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTX:CC - XORTX Presents New Proof of Concept Data at American Society of Nephrology

● Xanthine Oxidase Inhibition with XRx-008 Blocks Uric Acid Induced Increase in Total Kidney Weight in Polycystic Kidney Disease ● CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”)...
XRTX:CC - XORTX Announces Participation at Upcoming Investor Conferences

CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, ann...

XRTX:CC - XORTX Receives Further No Objection Letter from Health Canada

CALGARY, Alberta, Oct. 26, 2022 (GLOBE NEWSWIRE) --  XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...

XRTX:CC - XORTX Sponsored American Society of Nephrology Study Abstract Available Online

• Chronically Increased Uric Acid Accelerates Structural and Functional Changes in Polycystic Kidney Disease • CALGARY, Alberta, Oct. 25, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TS...
XRTX:CC - XORTX Announces Closing of US$5 Million Public Offering

CALGARY, Alberta, Oct. 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney ...

XRTX:CC - XORTX Announces US$5 Million Public Offering

CALGARY, Alberta, Oct. 04, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney ...

XRTX:CC - XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

CALGARY, Alberta, Sept. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical development stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney dise...
XRTX:CC - XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology - Kidney Week 2022

CALGARY, Alberta, Sept. 01, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease is ...

XRTX:CC - XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ...

XRTX:CC - XORTX Announces Pre-Phase 3 Meeting Date with US Food and Drug Administration

CALGARY, Alberta, Aug. 04, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ...
Previous 10 Next 10